Absolutely right Venus No place for false pride now what’s the purpose? No more management hubris please?? The only purpose of an Appeal however cogent the arguments for Du reversal is to engineer enough leverage for a well constructed exit strategy vis a negotiated settlement. Amrn cannot afford to bet on Appeal and loose it. Anyone who argues otherwise is allowing emotions to govern their reasoning... Thero and Kennedy have a lot of explaining to do as to why they allowed this Du judgement to ever spin out without an alternative...the risks were every bit as great then pre-Du judgement as they are now... bad strategy! Lets hope the Board of Directors, this board and all AMRN investors ( big and small) can together make the clowns in management do something right for a bloody change..negotiate a settlement HK
Quote: "Publicly Amarin's plan is then to compete with the generics with their own generic Vascepa in the U.S. and have partnerships in Europe. That sounds like a nightmare within a nightmare."
Why so? The perfect is the enemy of the good. The market for Vascepa is going to be mind blowing...A fraction of Vascepa sales could be worth more than the whole pie of another drug...Amarin is going to have tied up a lot of the suppliers and very likely could have lower costs in producing the drug to the point where it is no longer profitable for the generics..I have always and still believe Vascepa will pretty much sell itself..Most people want to live longer..You can not look at the first couple of months of sales particularly when we are under quarantine. Do we really need a partner in Europe...How bout using the Japanese model.Don't partner..Just open the dealerships employ the locals,,and have your people in charge of management..
The generics are not home yet..There is the very sticky subject of the fact Vascepa embodies a patented capsule which tends to retard the degradation of the EPA...Getting around those patents and complying with FDA requirements might lead to a couple of years or more delay or maybe the Generics will not get Judge Du in the next patent fight..
Market Data 
Markets 
AI
